Pharming Group N.V.
- BID
1.1505
- ASK
1.1645
- 11,267 Units1,750 Units
- 07/21, 21:52:01 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
36.39%
Market Cap
798.06 Mil.
P/E Ratio
385.41
Dividend Yield
0.00 %
Earnings per Share
0.00 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.1505 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:47:22 PM | |
| DAILY VOLUME (UNITS) | 1,500 | |
| DAILY HIGH / LOW | 1.1515 | 1.125 |
| PREV. DAY'S PRICE | 1.13 | (07/20) |
| CHANGE DAY BEFORE | +0.02 | 1.81 % |
| 52 WEEK HIGH / LOW | 1.795 (01/28) | 0.7905 (07/22) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.01 | -0.02 | 0.00 | 0.01 | 0.01 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 385.41 | 181.79 | 159.35 |
PRICE - BOOK RATIO | 3.49 | 2.95 | 4.24 | - | - |
PRICE - SALES RATIO | 2.99 | 2.26 | 3.20 | - | - |
PRICE - CASH FLOW RATIO | - | - | 24.21 | - | - |
Master Data
| WKN | A1H65A |
| ISIN | NL0010391025 |
| SYMBOL | PHGN |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Pharming Group N.V. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 707.78 Mil. |
| MARKET CAPITALISATION | 798.06 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -3.05 % | 0.80 % | -23.67 % | -23.80 % | 36.39 % | 2.26 % | 22.88 % | -17.34 % |
| HIGH | 1.17 | 1.28 | 1.49 | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 |
| LOW | 1.13 | 1.11 | 1.03 | 1.03 | 0.79 | 0.61 | 0.61 | 1.03 |
Dividende
pro Aktie
Pharming Group N.V. does not deliver dividend information
Company profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Structured products for Pharming Group N.V.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.